English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The neuropeptide Y (NPY) Y 1 receptor (Y 1 R) selective radioligand ( R )- N  α -(2,2-diphenylacetyl)- N  ω -[4-(2-[ 18 F]fluoropropanoylamino)butyl]aminocarbonyl- N -(4-hydroxybenzyl)argininamide ( [   18   F]23 ), derived from the high-affinity Y 1 R antagonist BIBP3226, was developed for imaging studies of Y 1 R-positive tumors. Starting from the argininamide core bearing amine-functionalized spacer moieties, a series of fluoropropanoylated and fluorobenzoylated derivatives was synthesized and studied for Y 1 R affinity. The fluoropropanoylated derivative 23 displayed high affinity ( K  i = 1.3 nM) and selectivity toward Y 1 R. Radiosynthesis was accomplished via 18 F-fluoropropanoylation, yielding [   18   F]23 with excellent stability in mice; however, the biodistribution study revealed pronounced hepatobiliary clearance with high accumulation in the gall bladder (&gt;100 %ID/g). Despite the unfavorable biodistribution, [   18   F]23 was successfully used for imaging of Y 1 R positive MCF-7 tumors in nude mice. Therefore, we suggest [   18   F]23 as a lead for the design of PET ligands with optimized physicochemical properties resulting in more favorable biodistribution and higher Y 1 R-dependent enrichment in mammary carcinoma.

Prototypic 18F-Labeled Argininamide-Type Neuropeptide Y Y1R Antagonists as Tracers for PET Imaging of Mammary Carcinoma

Prototypic ¹⁸F-Labeled Argininamide-Type Neuropeptide Y Y₁R Antagonists as Tracers for PET Imaging of Mammary Carcinoma